Pluri (PLUR) Total Non-Current Liabilities (2011 - 2025)
Pluri (PLUR) posted quarterly Total Non-Current Liabilities of $7.5 million for Q4 2025, down 74.56% year-over-year from $29.3 million in Q4 2024, and up 4.25% quarter-over-quarter from $7.2 million in Q3 2025.
Pluri (PLUR) Total Non-Current Liabilities (2011 - 2025) Analysis & Trends
Pluri (PLUR) has reported Total Non-Current Liabilities for 15 consecutive years, with $7.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities fell 74.56% year-over-year to $7.5 million; the TTM figure through Dec 2025 stood at $7.5 million (down 74.56% YoY), while the FY2025 annual figure was $7.2 million, down 75.66% from the prior year.
- Total Non-Current Liabilities climbed to $7.5 million in Q4 2025 per PLUR's latest filing, from $7.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $31.7 million in Q4 2021 and bottomed at $1.1 million in Q1 2021.
- Historically, Total Non-Current Liabilities has averaged $24.6 million across 5 years, with a median of $29.5 million in 2024.
- Annual changes were most pronounced in 2021 — Total Non-Current Liabilities surged 2737.27% — and 2025, when it slumped 76.85%.
- Pluri's Total Non-Current Liabilities stood at $31.7 million in 2021, then declined by 6.53% to $29.7 million in 2022, then advanced by 2.49% to $30.4 million in 2023, then declined by 3.55% to $29.3 million in 2024, then slumped by 74.56% to $7.5 million in 2025.
- Business Quant data shows PLUR's Total Non-Current Liabilities at $7.5 million in Q4 2025, $7.2 million in Q3 2025, and $7.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 7.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.46 Mn |
| Sep 30, 2025 | 7.16 Mn |
| Jun 30, 2025 | 7.22 Mn |
| Mar 31, 2025 | 31.22 Mn |
| Dec 31, 2024 | 29.34 Mn |
| Sep 30, 2024 | 30.92 Mn |
| Jun 30, 2024 | 29.66 Mn |
| Mar 31, 2024 | 30.02 Mn |
| Dec 31, 2023 | 30.42 Mn |
| Sep 30, 2023 | 29.18 Mn |
| Jun 30, 2023 | 29.88 Mn |
| Mar 31, 2023 | 29.98 Mn |
| Dec 31, 2022 | 29.68 Mn |
| Sep 30, 2022 | 27.84 Mn |
| Jun 30, 2022 | 29.05 Mn |
| Mar 31, 2022 | 31.16 Mn |
| Dec 31, 2021 | 31.75 Mn |
| Sep 30, 2021 | 24.48 Mn |
| Jun 30, 2021 | 24.87 Mn |
| Mar 31, 2021 | 1.12 Mn |